Skip to main content
. 2021 Oct 15;40:321. doi: 10.1186/s13046-021-02115-1

Fig. 4.

Fig. 4

Effects of ibrutinib on immune cells and tumor microenvironment. BTLA, B- and T-lymphocyte attenuator; IL-10, interleukin 10; NAMPT, Nicotinamide Phosphoribosyltransferase; PD-L1, programmed cell death protein ligand 1; TCR, T-cell receptor